Clinical Trials Browser

NIH × pazopanib × CNS × Clear all

NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2 Completed

35 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Phase 2 Terminated

7 enrolled 8 charts

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT01130623 2017-07-02

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

Phase 1 Withdrawn

CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma, Osteosarcoma

NCT00459381 2017-03-15

Pazopanib in Treating Patients With Recurrent Glioblastoma

Phase 2 Completed

35 enrolled 12 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00929903 2013-09-30

Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment

Phase 1 Completed

Optic Nerve Glioma